Smadja D, Abreu M
Front Neurosci. 2025; 19:1475376.
PMID: 39967803
PMC: 11832498.
DOI: 10.3389/fnins.2025.1475376.
Nasser N, Welsh C, Mitra A, Swan M
Cureus. 2023; 15(8):e42898.
PMID: 37664331
PMC: 10474849.
DOI: 10.7759/cureus.42898.
Fung W, Fasano A, Fearon C
Mov Disord Clin Pract. 2023; 10(Suppl 2):S9-S17.
PMID: 37637980
PMC: 10448146.
DOI: 10.1002/mdc3.13615.
Schneider S, Desai S, Phokaewvarangkul O, Rosca E, Sringean J, Anand P
J Neurol. 2023; 270(5):2409-2415.
PMID: 36943516
PMC: 10029788.
DOI: 10.1007/s00415-023-11661-x.
Alhumaid S, Mutair A, Busubaih J, Al Dossary N, Alsuliman M, Baltyour S
Infect Agent Cancer. 2022; 17(1):49.
PMID: 36096812
PMC: 9466313.
DOI: 10.1186/s13027-022-00459-7.
Safety profile of COVID-19 drugs in a real clinical setting.
Chiu M, Bhardwaj M, Sah S
Eur J Clin Pharmacol. 2022; 78(5):733-753.
PMID: 35088108
PMC: 8794611.
DOI: 10.1007/s00228-021-03270-2.
Emerging Psychiatric Themes in Post-COVID-19 Patients on a Psychiatry Consultation-liaison Service.
El Hayek S, Kassir G, Zalzale H, Gonzalez-Diaz J, Bizri M
Psychiatr Q. 2021; 92(4):1785-1796.
PMID: 34463904
PMC: 8405712.
DOI: 10.1007/s11126-021-09944-5.
New-Onset Movement Disorders Associated with COVID-19.
Brandao P, Grippe T, Pereira D, Munhoz R, Cardoso F
Tremor Other Hyperkinet Mov (N Y). 2021; 11:26.
PMID: 34277139
PMC: 8269765.
DOI: 10.5334/tohm.595.
De Novo Movement Disorders and COVID-19: Exploring the Interface.
Ghosh R, Biswas U, Roy D, Pandit A, Lahiri D, Ray B
Mov Disord Clin Pract. 2021; 8(5):669-680.
PMID: 34230886
PMC: 8250792.
DOI: 10.1002/mdc3.13224.
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.
Gatti M, De Ponti F, Pea F
CNS Drugs. 2021; 35(4):345-384.
PMID: 33866523
PMC: 8053373.
DOI: 10.1007/s40263-021-00811-2.
Myoclonus-Ataxia Syndrome Associated with COVID-19.
Shetty K, Jadhav A, Jayanthakumar R, Jamwal S, Shanubhogue T, Reddy M
J Mov Disord. 2021; 14(2):153-156.
PMID: 33819422
PMC: 8175811.
DOI: 10.14802/jmd.20106.
Disaster management of the psychological impact of the COVID-19 pandemic.
Sheek-Hussein M, Abu-Zidan F, Stip E
Int J Emerg Med. 2021; 14(1):19.
PMID: 33761863
PMC: 7988636.
DOI: 10.1186/s12245-021-00342-z.
Toxicity of psychotropic drugs in patients with COVID-19: A systematic review.
Sabe M, Dorsaz O, Huguelet P, Kaiser S
Gen Hosp Psychiatry. 2021; 70:1-9.
PMID: 33631694
PMC: 7890235.
DOI: 10.1016/j.genhosppsych.2021.02.006.
Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic.
Portela-Sanchez S, Sanchez-Soblechero A, Melgarejo Otalora P, Rodriguez Lopez A, Velilla Alonso G, Palacios-Mendoza M
Eur J Neurol. 2021; 28(10):3339-3347.
PMID: 33474816
PMC: 8013314.
DOI: 10.1111/ene.14748.
Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?.
Costa L, Santos B, Branco L
Eur J Pharmacol. 2020; 889:173629.
PMID: 33022271
PMC: 7832208.
DOI: 10.1016/j.ejphar.2020.173629.
A diagnostic confusion between Serotonin syndrome and Neuroleptic malignant syndrome.
Prakash S
Am J Emerg Med. 2020; 43:272-273.
PMID: 33008703
PMC: 7320697.
DOI: 10.1016/j.ajem.2020.06.046.
